Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers looking at multiple sclerosis investigate using drugs normally prescribed for other diseases.

Affecting 1 in 1,000 people, multiple sclerosis (MS) is an autoimmune disease in which the body’s immune system attacks its own brain and spinal cord.

Professor Lars Fugger’s research at the Nuffield Department of Clinical Neurosciences has found that a drug used to treat hypertension also has some efficacy against neurodegeneration, which is part of MS.

I've seen over the years that there is light at the end of the tunnel, and that if you just push, you will make a difference. - Professor Lars Fugger

MS seems to share some factors with two different groups of diseases: those involving the immune system, such as rheumatoid arthritis, psoriasis and type 1 diabetes; and those involving neurodegenerative conditions of the brain, as in Parkinson’s disease and Alzheimer’s. Data sets relating to all these are being analysed for any patterns or commonalities which could help in identifying new therapeutic strategies against MS.

Read more on the Oxford Thinking website...

Similar stories

New insights into the effect of exposure to dim light in the evening on the biology of the sleep-wake cycle

A new study has revealed more about how exposure to dim light in the evening affects circadian health. The findings emphasise the need to optimise our artificial light exposure if we are to avoid shifting our biological clocks.

Blood lipoprotein levels linked to future risk of amyotrophic lateral sclerosis

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.

International study finds insomnia, anxiety and depression very prevalent during first phase of COVID-19 pandemic

Researchers are recommending public health interventions to reduce the long-term adverse outcomes associated with chronic insomnia and mental health problems.

Alexander Davies wins top UKRI Future Leaders Fellowship

Alex is one of eight Oxford University academics who have been awarded significant financial funding from the UKRI Future Leaders Fellowships Scheme

New study on link between autoimmunity and pain

Patients with autoantibodies which target neuronal proteins can have pain as an under-recognised clinical manifestation.